Keystat Report issue

For profit Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04463251
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Keystat, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

rph-104 (1 trial)

Drugs in Phase 2 Trials (1)

olokizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Inflammation (Phase 2)

Myocardial Infarction (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2